Prellis Biologics is a biotechnology company that specializes in 3D bioprinting technology for tissue engineering and regenerative medicine applications. They have developed a proprietary laser-based bioprinting platform capable of creating complex three-dimensional structures with high resolution and precision. Prellis focuses on building vascularized tissues and organs, as their technology allows for the precise placement of cells and biomaterials to mimic the natural architecture of tissues and organs, including intricate vascular networks. By enabling the fabrication of vascularized tissues, Prellis aims to address key challenges in organ transplantation, tissue repair, and drug discovery. Their innovative approach holds promise for advancing the field of regenerative medicine and ultimately improving patient outcomes. Additionally, Prellis is actively engaged in collaborative research and partnerships to further develop and commercialize their bioprinting technology for various biomedical applications.
